{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:14:51Z","timestamp":1792808091766,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people living with human immunodeficiency virus (PLWH), however this high-cancer-risk population has often been excluded from groundbreaking cancer ICI trials. Our study aimed to characterize the current rate of exclusion and conditional inclusion of PLWH in cancer ICI trials by tumor type, trial phase, and year. ClinicalTrials.gov cancer ICI trials with planned starts between 1\/1\/2019 and 10\/20\/2020 were identified. Based on trial eligibility criteria, trials were categorized as \u201cexcluded\u201d if PLWH could not enroll, \u201cconditionally included\u201d if only PLWH with adequate immune function were allowed, or \u201cincluded\/not specified\u201d if HIV was not mentioned in the eligibility criteria. Trials from 2014 were separately collected for comparison over time. The number of trials excluding PLWH were compared to the included\/not specified group using Fisher\u2019s exact test. Of 809 trials analyzed from 2019 to 2020, 74.4% excluded, 6.9% conditionally included, and 18.7% included\/did not specify PLWH. Early phase trials excluded PLWH more frequently than late phase trials. The 2019\u20132020 trial cohort showed no significant change in exclusion of PLWH compared to 2014. Despite increasing evidence for safe and effective ICI use for PLWH, most cancer ICI trials exclude PLWH and few studies permit PLWH to participate, even if HIV is well-controlled.<\/jats:p>","DOI":"10.1038\/s41598-021-86081-w","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:04:44Z","timestamp":1616497484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials"],"prefix":"10.1038","volume":"11","author":[{"given":"Kruti B.","family":"Vora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"86081_CR1","unstructured":"UNAIDS. Global HIV & AIDS Statistics\u20142020 Fact Sheet. https:\/\/www.unaids.org\/en\/resources\/fact-sheet (UNAIDS, 2020)."},{"key":"86081_CR2","unstructured":"UNAIDS. UNAIDS Urges Everyone to Make Some Noise for Zero Discrimination. https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2017\/february\/20170301_zero-discrimination-day (UNAIDS, 2017)."},{"key":"86081_CR3","unstructured":"Global Network of People Living with HIV (GNP+). The People Living with HIV Stigma Index. https:\/\/www.stigmaindex.org\/ (GNP+, 2020)."},{"issue":"7","key":"86081_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","volume":"5","author":"MR Cook","year":"2019","unstructured":"Cook, M. R. & Kim, C. Safety and efficacy of immune checkpoint inhibitory therapy in patients with HIV infection and advanced-stage cancer: A systemic review. JAMA Oncol. 5(7), 1049\u20131054 (2019).","journal-title":"JAMA Oncol."},{"issue":"9581","key":"86081_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"AE Grulich","year":"2007","unstructured":"Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370(9581), 59\u201367 (2007).","journal-title":"Lancet"},{"issue":"6","key":"86081_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s11908-014-0406-0","volume":"16","author":"CC Wang","year":"2014","unstructured":"Wang, C. C., Silverberg, M. J. & Abrams, D. I. Non-AIDS-defining malignancies in the HIV-infected population. Curr. Infect. Dis. 16(6), 406 (2014).","journal-title":"Curr. Infect. Dis."},{"issue":"7","key":"86081_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/M14-2768","volume":"163","author":"MJ Silverberg","year":"2015","unstructured":"Silverberg, M. J. et al. Cumulative incidence of cancer among persons with HIV in North America: A cohort study. Ann. Intern. Med. 163(7), 507\u2013518 (2015).","journal-title":"Ann. Intern. Med."},{"issue":"21","key":"86081_CR8","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","volume":"33","author":"AE Coghill","year":"2015","unstructured":"Coghill, A. E., Shiels, M. S., Suneja, G. & Engels, E. A. Elevated cancer-specific mortality among HIV-infected patients in the United States. J. Clin. Oncol. 33(21), 2376\u20132383 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"86081_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1158\/1055-9965.EPI-16-0964","volume":"26","author":"AE Coghill","year":"2017","unstructured":"Coghill, A. E., Pfeiffer, R. M., Shiels, M. S. & Engels, E. A. Excess mortality among HIV-infected individuals with cancer in the United States. Cancer Epidemiol. Biomark. Prev. 26(7), 1027\u20131033 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"11","key":"86081_CR10","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hern\u00e1ndez-Ram\u00edrez","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez, R. U., Shiels, M. S., Dubrow, R. & Engels, E. A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: A population-based, registry-linkage study. Lancet HIV 4(11), e495\u2013e504 (2017).","journal-title":"Lancet HIV"},{"key":"86081_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan, R. & Uldrick, T. S. HIV-associated cancers and related diseases. N. Engl. J. Med. 378, 1029\u20131041 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"86081_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick, T. S. et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014A phase 1 study. JAMA Oncol. 5(9), 1332\u20131339 (2019).","journal-title":"JAMA Oncol."},{"issue":"7","key":"86081_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","volume":"13","author":"L Ostios-Garcia","year":"2018","unstructured":"Ostios-Garcia, L. et al. Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer. J. Thorac. Oncol. 13(7), 1037\u20131042 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"86081_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","volume":"6","author":"M Gonzalez-Cao","year":"2020","unstructured":"Gonzalez-Cao, M. et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection. JAMA Oncol. 6(7), 1063\u20131067 (2020).","journal-title":"JAMA Oncol."},{"key":"86081_CR15","unstructured":"Food and Drug Administration. Cancer clinical trial eligibility criteria: Patients with HIV, hepatitis B virus, or hepatitis C virus infections. in Federal Register 41990\u201341992 (2020)."},{"key":"86081_CR16","unstructured":"American Society of Clinical Oncology, Friends of Cancer Research. Cancer Clinical Trial Eligibility Criteria: Series of Four Draft Guidances. https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/blog-release\/pdf\/ASCO-FOCR-Comments-FDA-Eligibility-Criteria_03May2019.pdf. Accessed 15 October 2020 (American Society of Clinical Oncology, 2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86081-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86081-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86081-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:51:41Z","timestamp":1670046701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86081-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86081"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86081-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"12 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Awad reports grants and personal fees from Genentech, grants and personal fees from Bristol-Myers Squibb, personal fees from Merck, grants and personal fees from AstraZeneca, grants from Lilly, personal fees from Maverick, personal fees from Blueprint Medicine, personal fees from Syndax, personal fees from Ariad, personal fees from Nektar, personal fees from Gritstone, personal fees from ArcherDX, personal fees from Mirati, personal fees from NextCure, outside the submitted work. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6637"}}